Review of marine-derived compounds targeting hallmarks of aging
This review examines marine-derived bioactive molecules reported to affect lifespan or hallmarks of aging and to show therapeutic potential in age-related diseases, but notes that only a limited number have reached late-stage clinical trials. [1]
Automatic summary · not editorially reviewed
The key findings
The review describes marine-derived molecules as studied for antioxidant, anti-inflammatory and cytoprotective properties targeting aging pathways. [1]
The review aims to cover marine molecules reported to extend lifespan and to target hallmarks of aging. [1]
Several compounds showed promising preclinical results, but only a limited number reached late-stage clinical trials. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Marine-derived bioactive molecules and age-related diseases, as described in the review abstract
- Summary based on
- Study abstract
Marine molecules and aging hallmarks reviewed
The authors describe aging as a multifactorial biological process with progressive cellular and tissue damage and functional decline across organs. They present marine-derived molecules as a structurally diverse, multifunctional group studied for antioxidant, anti-inflammatory and cytoprotective properties. According to the review, these compounds target pathways such as cellular senescence, genomic instability, impaired autophagy and chronic inflammation.
Supporting source [1]
Lifespan and age-related disease aims
The review states three aims: to explore marine-derived bioactive molecules reported to extend lifespan, to summarize studies showing they target one or more hallmarks of aging, and to highlight compounds with therapeutic potential in age-related diseases. These diseases are listed as neurodegenerative, cardiovascular, metabolic, cancer, musculoskeletal and chronic pulmonary disorders. The authors call their multitarget activity attractive for prevention or treatment of age-related diseases.
Supporting source [1]
Preclinical promise, few late-stage trials
Several compounds showed promising results in preclinical studies, according to the abstract. However, only a limited number have progressed to late-stage clinical trials. The authors therefore emphasize the need for further translational research that may lead to new anti-aging therapeutic strategies. The abstract does not name individual compounds, report effect sizes or describe trial details.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract names no individual compounds, effect sizes, study designs or trial details, and preclinical findings do not establish human lifespan or disease benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Maria Elisa Giuliani, Chiara Giordani, Gianmarco Bertoni, Emanuele Francini, Giorgia Bigossi, Giovanni Lai, Serena Marcozzi, Sunday Segun Alimi, Davide Perini, Andrea Piccinini, Sara Ristori, Elisa Bientinesi, Francesca Barone, Maurizio Cardelli, Cesare Indiveri, Mariafrancesca Scalise, Daniela Monti, Marco Malavolta · doi.org